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Dedication ((optional)) 
The 3-azabicyclo[3.1.0]hexane is a common motif in natural 
products.[1-6] Furthermore this rigid framework represents a 
privileged class of pharmacologically active compounds, often 
showing enhanced binding affinities with their targets (Figure 
1).[7] These bicycles also represent conformationally restricted 
analogues of piperidines (e.g. trovafloxacin).[8] When substituted 
with a carboxylic acid moiety, they resemble conformationally 
restricted analogues of glutamate, gamma-amino butyric acid 
(GABA) or α/β-proline analogues (Figure 2).[9] 
Numerous methods have been developed for the construction 
of azabicyclo[3.1.0]hexanes.[10] These include the Kulinkovich/de 
Meijere reaction[11,12], cyclisation of tethered amines with metals 
(Pd[13], Ru[14], Rh[15], Ag[16]), cyclisation of tethered 
cyclopropanes[17], and the Simmons-Smith[18]/Corey-
Chaykovsky[19]/sulfur ylide-Au[20] cyclopropanations. These 
methods are usually only effective in the synthesis of one specific 
type of scaffold.  
We were keen to develop a general strategy that could deliver 
3-azabicyclo[3.1.0]hexanes with a range of functional groups in a 
range of positions. Our design plan for the synthesis of the 
scaffold was to effect a tandem process initiated by conjugate 
addition of an unsaturated amine 1 to vinyl sulfonium salt 2, 
generated in situ from the stable and crystalline salt 3 (Scheme 1). 
The intermediate sulfur ylide 4 would undergo intramolecular 
addition to the Michael acceptor to give a sulfonium enolate 5 
which would ring close to the cyclopropane 6.  
 
Figure 1. Selected examples of important bicyclo[3.1.0]hexanes. 
 
 
 
 
 
 
 
Figure 2. Conformationally restricted scaffolds discussed in this work. 
This tandem process is related to the previously described 
reactions that bear aldehydes or imines in place of Michael 
acceptors, giving fused bicyclic epoxides and aziridines 
respectively.[21,22] However, the more complex reaction with 
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Scheme 1. Proposed mechanism of the reaction. (B = Base) 
Table 1: Scope of the transformation. 
All yields are isolated yields and dr is determined by 1H NMR of the crude; [a] Yield 
of TBS deprotected product including an in situ deprotection with TBAF (5 equiv) 
added after 15 h; [b] reaction at 0 °C, if run at rt yield is 75% and d.r. is 7:1; [c] 
minor traces of other diastereomer visible in 1H NMR. 
Michael acceptors (leading to products with additional 
stereogenic centers) has not been previously reported.[23] The 
potential for a very rapid increase in molecular complexity from 
simple starting materials was an additional attractive feature of 
the chemistry. In this paper, we report the successful realisation of 
this strategy and the formation of azabicyclo[3.1.0]hexanes with 
surprisingly high diastereoselectivity. 
Our studies began with the preparation of a diverse array of 
allylic amines. The allylic amines 1a-g were prepared in one step 
using either cross-metathesis[24] or Wittig chemistry. Similarly, 
1h-j were synthesized in two steps from commerically available 
amino acid-derived methyl esters through a DIBAL-H 
reduction/Wittig reaction sequence. Allylic amines 1k, and 1l 
with the appropriate protecting groups required several steps[25] 
whilst 1m was available in one step from reaction of 
dihydrocinnamaldehyde with a vinylchromium nucleophile[26] 
(see SI for details).  
The reaction of unsaturated amide 1a with the stable and 
crystalline salt 3 was initially tested. After optimisation of the 
process (see supporting information) a set of conditions were 
established (method A), that led to moderate-high yields of the 
[3.1.0] bicycles with complete diastereoselectivity (Table 1).[27] 
For example, unsaturated amide 1a gave the cyclopropane 6a in 
62% yield as a single diastereomer. The Michael acceptors tested 
bore a range of electron-withdrawing groups, including Me and 
tBu esters, ketones, amides and nitriles (6a-6e). Furthermore, in 
the case of the unsubstituted allylic amide, the N-Cbz carbamate 
1f[28] could also be employed in place of the tosyl protecting 
group leading to the pyrrolidine 6f. The piperidine 6g was also 
accessible using the same process and again was formed with 
complete diastereoselectivity. 
The method was further extended to a range of α-substituted 
allylic amines (1h-1m), although in this case NaH was found to 
be superior to DBU (method B). With a small substituent (Me, 
1h), the azabicyclo[3.1.0] hexane 6h was formed with low 
diastereoselectivity but with larger substituents (1i, 1j) the 
adducts (6i, 6j) were formed with essentially complete 
diastereoselectivity. In terms of the N-protecting group, with α-
substituted allylic amines, it was not possible to use the Cbz or 
Boc groups, but the more easily cleavable[28] 1-naphthyl or SES 
sulfonamides (1k, 1l) worked well giving similarly high yield and 
diastereoselectivity. Interestingly, allylic alcohol 1m could also be 
used and gave the tetrahydrofuran 6m, again with high selectivity. 
The methodology readily lent itself to the preparation of 
enantioenriched products, as illustrated with 6k, 6l, since the α-
substituted allylic amines are easily obtained from chiral amino 
acids (serine in this case). 
Expanding this methodology further, we were able to utilise 
easily accessible aza-Morita-Baylis-Hillman adducts 7a-7c[29] 
(one step from the acrylate), as starting materials for the 
cyclisation. These reactions now lead to the formation of β-
proline-derived fused cyclopropanes 8a-8c (Table 2).[30]  
Whilst unsaturated esters 7a and 7b worked well, giving the 
corresponding adducts 8a and 8b, respectively, in high yield and 
very high diastereoselectivity, unsaturated ketone (7c) behaved 
differently. In this case the major product was the epoxy-
annulation adduct 9. Evidently, after 1,4-addition of the amide 7c 
to the vinyl sulfonium salt 1, the ylide intermediate reacts in a 
more favoured 6-exo-trig mode with the ketone moiety, rather 
than the desired 6-endo-trig mode with the alkene. Nevertheless, 
the pyrrolidine 8c was formed with high diastereoselectivity as 
before. The methodology readily lends itself to asymmetric 
synthesis, since the aza-Morita-Baylis-Hillman adducts 7a, 7b are 
obtainable using asymmetric organocatalysis.[31] This was 
illustrated in the use of (+)-7a (82% ee), which gave the [3.1.0] 
bicycle (+)-8a without measurable racemization, which was 
increased to >99% ee after recrystallization. 
 
 
 3 
Table 2: Reactivity of (aza)-Morita-Baylis-Hillman adducts. 
All yields are isolated yields and dr is determined by 1H NMR of the crude; [a] The 
ee was determined by chiral SFC, see SI for full details. 
 
The relative stereochemistry of cyclopropanes 6g, 6i, and 8a 
were determined by X-ray analysis and related compounds were 
assigned by analogy (see Supporting information for details). It is 
believed that the steps prior to ring closure are reversible and that 
the selectivity is determined in the non-reversible ring closure 
step which forms the cyclopropane. The origin of selectivity of 
the two classes of substrates 1 and 7 can be rationalised by 
considering the non-bonded steric interactions in the TSs where 
the less hindered X1 and Y1 are favoured over X2 and Y2, which 
subsequently leads to the preferred formation of trans (6h-6m) 
and cis (8a-8c) isomers (Scheme 2). 
Scheme 2. Model for diastereoselectivity in the formation of 6 and 8 
 
The cyclopropyl-annulation reaction was further extended 
to include the medicinally important CF3 group. Thus, reaction of 
1a with the CF3-substituted vinyl sulfonium salt 10
[32] gave the 
CF3-substitued [3.1.0] pyrrolidine 11
[33], again with essentially 
complete diastereoselectivity[21i] (Scheme 3).  
 
 
 
 
 
 
 
 
Scheme 3. Formation of 11 with β-CF3 vinylsulfonium salt 10. 
 
 
 
 
 
 
Scheme 4. Oxidation to α,β-amino acid derivative 12. 
 
The synthetic utility of the methodology is illustrated through 
a range of functional group transformations of several of the 
[3.1.0] pyrrolidines. For example, oxidative cleavage of the Ph 
group[34] in 8a gave pyrrolidine 13 which is both an α- and a β-
amino acid derivative (Scheme 4).[35] 
Deprotection and oxidation of 6l gave the conformationally 
locked glutamic acid analogue (Scheme 5).[36]  
Scheme 5. Deprotection and transformation of 6l. a) CsF (5 equiv), DMF (0.1 M), 
95 °C, 4 h then b) Boc2O(1.2 equiv), NEt3 (3 equiv), CH2Cl2, rt, 2 h, 62% over 2 
steps; c) PDC (4 equiv), DMF (0.5 M), Ref[36] 63%. 
 
Finally, pyrrolidine 6f was converted into 6-amino-3-
azabicyclo[3.1.0]hexan-3-ium chloride 16, an intermediate used 
in the synthesis of trovafloxacin, a potent antibiotic.[4] Thus, 
saponification of the ester 6f, followed by the Schmidt reaction 
with diphenyl phosphoryl azide (DPPA) gave pyrrolidine 15. 
Finally, hydrogenolysis gave amino pyrrolidine 16 in just a few 
synthetic steps (Scheme 6).  
Scheme 6. Formal synthesis of the trovafloxacin precursor 16. a) aq. NaOH (1 M), 
THF, rt, 15 h then b) DPPA (1.1 equiv), NEt3 (1.1 equiv), BnOH (5 equiv), PhMe 
(0.25 M), 90 C, 1.5 h, 62% (0.3 g scale) over 2 steps; c) H2 (1 atm), Pd/C (cat.), HCl 
in Et2O (2 M, 3 equiv), MeOH, rt, 3 h, 99%. 
 
In conclusion we have developed a novel, efficient and 
versatile route for the formation of cyclopropane-fused 
heterocycles from easily available starting materials. In 
comparison to previous methods, this protocol enables the 
synthesis of a more diverse range of substituted and 
functionalized [3.1.0] scaffolds with very high diastereoselectivity. 
There is considerable interest in exploring this class of bioactive 
compounds, which should now be enabled by the methodology 
described herein.  
Experimental Section 
A stirred solution of amine or alcohol 1 (1.0 equiv.) and diphenyl bromoethyl 
sulfonium salt 3 (1.25 equiv.) in anhydrous solvent (0.1 M) at room temperature 
under inert atmosphere was treated with base (3.5 equiv.) and stirred for the 
indicated time (until complete consumption of starting material was detected by 
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HPLC or TLC). The reaction mixture was then quenched with 10% aqueous citric 
acid solution (15 mL/mmol) and the aqueous was extracted with CH2Cl2 (3 × 30 
mL/mmol). The combined organic layers were washed with brine (30 mL/mmol), 
dried (MgSO4) and concentrated in vacuo. The crude reaction mixture was purified 
by flash chromatography, eluting with either EtOAc/n-pentane or Et2O/n-pentane to 
give the desired product. 
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